Investor Presentaiton

III Key Investment Highlights 6 Robust Financial Performance Robust financial performance with double digit top line and bottom line growth Gross Revenue¹ | EGP mn Gross Profit | EGP mn, % EBITDA & Margin | EGP mn, % CAGR 31% 9,818 7,372 5,439 4,302 13,678 16,941 CAGR 36% 8.6% 8.4% 8.7% 7.9% 7.2% 7.3% 1,440 569 394 307 826 1,124 CAGR 44% 3.2% 2.9% 2.9% 229 155 122 4.6% 4.2% 4.2% 750 556 406 2014 2015 2016 2017 2018 20 19 2014 2015 2016 2017 2018 2019 2014 2015 2016 2017 2018 2019 0.9% Net Profit & Margin | EGP mn, % CAGR 54% 1.97% 1.98% 1.8% 329 1.4% 1.1% 102 57 38 170 263 ROE % 36% 32% 33% 47% In equity from IPO proceeds Return on Fixed Assets | % 42% 27% 27% 37% 63% 89% 34% 29% 2014 2015 2016 2017 2018 2019 2014 2015 2016 2017 2018 2019 2014 2015 2016 2017 2018 2019 ibnsinapharma Source: Company Management (1): Pro forma gross revenue includes part of 3PL revenue that was stated as other income until 2016 20 20

View entire presentation